BioCentury | Mar 6, 2014
Targets & Mechanisms

Heart cells: no longer undivided

...Phase I/II VentriNova Inc. VN-100 Adenoviral vector encoding cyclin A2 (CCNA2) Myocardial infarction (MI) Preclinical NanoCor Therapeutics Inc....
BioCentury | May 28, 2007
Emerging Company Profile

Tempo: Two-in-one approach

Differences in dosing schedules between angiogenesis inhibitors and chemotherapeutics and the fact that anti-angiogenics reduce the vasculature that delivers chemo to tumors can make optimizing the combination difficult. Tempo Pharmaceuticals Inc. believes its Nanocell drug...
Items per page:
1 - 2 of 2
BioCentury | Mar 6, 2014
Targets & Mechanisms

Heart cells: no longer undivided

...Phase I/II VentriNova Inc. VN-100 Adenoviral vector encoding cyclin A2 (CCNA2) Myocardial infarction (MI) Preclinical NanoCor Therapeutics Inc....
BioCentury | May 28, 2007
Emerging Company Profile

Tempo: Two-in-one approach

Differences in dosing schedules between angiogenesis inhibitors and chemotherapeutics and the fact that anti-angiogenics reduce the vasculature that delivers chemo to tumors can make optimizing the combination difficult. Tempo Pharmaceuticals Inc. believes its Nanocell drug...
Items per page:
1 - 2 of 2